Literature DB >> 16106132

Angiotensin-converting enzyme inhibitor use in the year 2005.

Domenic A Sica1.   

Abstract

The angiotensin-converting enzyme (ACE) inhibitor drug class is one with considerable staying power. ACE inhibitors are not only well established antihypertensive agents but also are compounds that fairly regularly provide end-organ protection. Several of the ACE inhibitors are entangled in an active debate regarding class effect. Class effect for ACE inhibitors is a hopelessly confused term because its definition is not standardized and is subject to interpretation that in many cases is self-serving. For the most part, ACE inhibitor side effects are readily identifiable, and management strategies put in place can be logical and sequential. The future of this drug class remains bright. Other drug classes, such as angiotensin receptor blockers, have narrowed-but not entirely closed-the outcomes gap that exists between these two drug classes.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16106132      PMCID: PMC8109555          DOI: 10.1111/j.1524-6175.2005.04598.x

Source DB:  PubMed          Journal:  J Clin Hypertens (Greenwich)        ISSN: 1524-6175            Impact factor:   3.738


  15 in total

1.  Renal considerations in angiotensin converting enzyme inhibitor therapy: a statement for healthcare professionals from the Council on the Kidney in Cardiovascular Disease and the Council for High Blood Pressure Research of the American Heart Association.

Authors:  A C Schoolwerth; D A Sica; B J Ballermann; C S Wilcox
Journal:  Circulation       Date:  2001-10-16       Impact factor: 29.690

2.  The addition of doxazosin to the therapeutic regimen of hypertensive patients inadequately controlled with other antihypertensive medications: a randomized, placebo-controlled study.

Authors:  H R Black; J S Sollins; J L Garofalo
Journal:  Am J Hypertens       Date:  2000-05       Impact factor: 2.689

3.  Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial--Lipid Lowering Arm (ASCOT-LLA): a multicentre randomised controlled trial.

Authors:  Peter S Sever; Björn Dahlöf; Neil R Poulter; Hans Wedel; Gareth Beevers; Mark Caulfield; Rory Collins; Sverre E Kjeldsen; Arni Kristinsson; Gordon T McInnes; Jesper Mehlsen; Markku Nieminen; Eoin O'Brien; Jan Ostergren
Journal:  Lancet       Date:  2003-04-05       Impact factor: 79.321

4.  Randomised trial of a perindopril-based blood-pressure-lowering regimen among 6,105 individuals with previous stroke or transient ischaemic attack.

Authors: 
Journal:  Lancet       Date:  2001-09-29       Impact factor: 79.321

5.  The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report.

Authors:  Aram V Chobanian; George L Bakris; Henry R Black; William C Cushman; Lee A Green; Joseph L Izzo; Daniel W Jones; Barry J Materson; Suzanne Oparil; Jackson T Wright; Edward J Roccella
Journal:  JAMA       Date:  2003-05-14       Impact factor: 56.272

6.  Efficacy of perindopril in reduction of cardiovascular events among patients with stable coronary artery disease: randomised, double-blind, placebo-controlled, multicentre trial (the EUROPA study).

Authors:  K M Fox
Journal:  Lancet       Date:  2003-09-06       Impact factor: 79.321

7.  Comparison of effects of enalapril plus hydrochlorothiazide versus standard triple therapy on renal function in renovascular hypertension.

Authors:  S S Franklin; R D Smith
Journal:  Am J Med       Date:  1985-09-27       Impact factor: 4.965

8.  Plasma renin measurement in the management of hypertension: the V and R hypothesis.

Authors:  Marvin Moser; Joseph L Izzo
Journal:  J Clin Hypertens (Greenwich)       Date:  2003 Nov-Dec       Impact factor: 3.738

9.  Antihypertensive utility of perindopril in a large, general practice-based clinical trial.

Authors:  Stevo Julius; Jay N Cohn; Joel Neutel; Michael Weber; Prasad Turlapaty; Yannan Shen; Victor Dong; Alicia Batchelor; Hjalmar Lagast
Journal:  J Clin Hypertens (Greenwich)       Date:  2004-01       Impact factor: 3.738

Review 10.  Angiotensin-converting enzyme inhibitors side effects--physiologic and non-physiologic considerations.

Authors:  Domenic A Sica
Journal:  J Clin Hypertens (Greenwich)       Date:  2004-07       Impact factor: 3.738

View more
  2 in total

Review 1.  Therapeutic potential of quercetin to decrease blood pressure: review of efficacy and mechanisms.

Authors:  Abigail J Larson; J David Symons; Thunder Jalili
Journal:  Adv Nutr       Date:  2012-01-05       Impact factor: 8.701

Review 2.  Quercetin: A Treatment for Hypertension?-A Review of Efficacy and Mechanisms.

Authors:  Abigail J Larson; J David Symons; Thunder Jalili
Journal:  Pharmaceuticals (Basel)       Date:  2010-01-19
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.